Literature DB >> 165511

Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells.

A Adams, T Lindahl.   

Abstract

A high-density fraction of high-molecular-weight DNA was isolated from the human lymphoid cell line Raji. This cell line contains 50 to 60 virus genome equivalents of Epstein-Barr virus DNA per cell, and the high-density DNA fraction was 10-fold enriched in such viral sequences. Sedimentation analysis on neutral glycerol gradients, followed by hybridization experiments with viral complementary RNA, showed that most of the intracellular viral DNA sequences in this material did not cosediment with the cellular DNA, but were recovered as two distinct species with sedimentation coefficients of 100 S and 65 S. These two forms sediment 1.70-1.75 and 1.10-1.12 times as fast as the linear Epstein-Barr virus DNA from virus particles, and thus have the hydrodynamic properties of a covalently closed circular form and a nicked (containing single-strand breaks) circular form of the virus genome. The 100S form also behaved as a covalently closed circular EBV DNA molecule on gradient centrifugation in CsC1/propidium diiodide, It would appear that latent Epstein-Barr virus DNA has the properties of a mammalian episome, and that both nonintegrated and integrated viral DNA sequences can be isolated from carrier cells.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 165511      PMCID: PMC432559          DOI: 10.1073/pnas.72.4.1477

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  MOLECULAR MECHANISMS OF GENETIC RECOMBINATION IN BACTERIOPHAGE. II. JOINING OF PARENTAL DNA MOLECULES OF PHAGE T4.

Authors:  J I TOMIZAWA; N ANRAKU
Journal:  J Mol Biol       Date:  1964-04       Impact factor: 5.469

2.  A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE.

Authors:  J V PULVERTAFT
Journal:  J Clin Pathol       Date:  1965-05       Impact factor: 3.411

3.  Linear association between cellular DNA and Epstein-Barr virus DNA in a human lymphoblastoid cell line.

Authors:  A Adams; T Lindahl; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

4.  Homology between Epstein-Barr virus DNA and viral DNA from Burkitt's lymphoma and nasopharyngeal carcinoma determined by DNA-DNA reassociation kinetics.

Authors:  M Nonoyama; J S Pagano
Journal:  Nature       Date:  1973-03-02       Impact factor: 49.962

5.  Fate of virus DNA in the abortive infection of human lymphoid cell lines by Epstein-Barr virus.

Authors:  U Jehn; T Lindahl; C Klein
Journal:  J Gen Virol       Date:  1972-09       Impact factor: 3.891

6.  Separation of Epstein-Barr virus DNA from large chromosomal DNA in non-virus-producing cells.

Authors:  M Nonoyama; J S Pagano
Journal:  Nat New Biol       Date:  1972-08-09

7.  Appearance of Epstein-Barr virus-associated antigens in infected Raji cells.

Authors:  L Gergely; G Klein; I Ernberg
Journal:  Virology       Date:  1971-07       Impact factor: 3.616

8.  Two-colour immunofluorescence studies on EBV-determined antigens.

Authors:  G Klein; L Gergely; G Goldstein
Journal:  Clin Exp Immunol       Date:  1971-04       Impact factor: 4.330

9.  Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies.

Authors:  T Lindahl; G Klein; B M Reedman; B Johansson; S Singh
Journal:  Int J Cancer       Date:  1974-06-15       Impact factor: 7.396

10.  The use of an ethidium analogue in the dye-buoyant density procedure for the isolation of closed circular DNA: the variation of the superhelix density of mitochondrial DNA.

Authors:  B Hudson; W B Upholt; J Devinny; J Vinograd
Journal:  Proc Natl Acad Sci U S A       Date:  1969-03       Impact factor: 11.205

View more
  70 in total

1.  Quantitative analysis of latent human cytomegalovirus.

Authors:  B Slobedman; E S Mocarski
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Sp1 binds to the precise locus of end processing within the terminal repeats of Epstein-Barr virus DNA.

Authors:  R Sun; T A Spain; S F Lin; G Miller
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.

Authors:  A Marchini; J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

4.  DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA.

Authors:  D Given; D Yee; K Griem; E Kieff
Journal:  J Virol       Date:  1979-06       Impact factor: 5.103

5.  Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection.

Authors:  A L Powell; W King; E Kieff
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

Review 6.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

7.  Size heterogeneity of EBV and mitochondrial DNAs in Burkitt's lymphoma lines.

Authors:  D Kinchington; B E Griffin
Journal:  Nucleic Acids Res       Date:  1987-12-23       Impact factor: 16.971

8.  Amounts of Epstein-Barr virus DNA in somatic cell hybrids between burkitt lymphoma-derived cell lines.

Authors:  M Andersson
Journal:  J Virol       Date:  1975-11       Impact factor: 5.103

9.  Nucleic acid renaturation and restriction endonuclease cleavage analyses show that the DNAs of a transforming and a nontransforming strain of Epstein-Barr virus share approximately 90% of their nucleotide sequences.

Authors:  B Sugden; W C Summers; G Klein
Journal:  J Virol       Date:  1976-05       Impact factor: 5.103

10.  Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle.

Authors:  Shih-Hsin Chiu; Meng-Chuan Wu; Chung-Chun Wu; Yu-Ching Chen; Su-Fang Lin; John T-A Hsu; Chung-Shi Yang; Ching-Hwa Tsai; Kenzo Takada; Mei-Ru Chen; Jen-Yang Chen
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.